Given that the RARA ligand ATRA induces loss of MYB combined with cell death in ACC cells (31) and given that, like BPDCN, ACC also features recurrent MYB fusions (7, 8), we wondered whether BPDCN would show sensitivity to ATRA treatment. This evidence concerns the gene RARA and adrenal cortex carcinoma.